Median age (range) – years | 65.4 (25-87) |
Older than 70 years – n (%) | 47 (48.9%) |
Male gender –n (%) | 84 (60.9) |
Average body weight (range) – kilograms | 79.5 (46 – 138) |
ECOG performance status –n (%) |
0 | 53 (38.4) |
1 | 71 (51.4) |
2 | 12 (8.7) |
3 | 2 (1.4) |
Anatomic site of primary |
Cutaneous | 116 (84.1) |
Ocular | 8 (5.8) |
Mucosal | 7 (5.1) |
Unknown primary | 7 (5.1) |
Actionable mutation –n (%) |
Wild type | 94 (68.1) |
BRAF V600E | 22 (15.9) |
BRAF V600K/M | 3 (2.2) |
NRAS | 3 (2.2) |
Not provided | 16 (11.6) |
Elevated baseline LDH level (> 4.31 microkat/L) – n (%) | 36 (26.1) |
Elevated baseline S100 level (> 0.105 microg/L) – n (%) | 72 (52.2) |
Metastatic stage – n (%)* |
M1a (0) | 28 (20.3) |
M1a (1) | 6 (4.3) |
M1b (0) | 29 (21.0) |
M1b (1) | 2 (1.4) |
M1c (0) | 32 (23.2) |
M1c (1) | 22 (15.9) |
M1d (0) | 13 (9.4) |
M1d (1) | 6 (4.3) |
Organs with metastatic involvement –n (%) |
1 | 47 (34.1) |
2 | 52 (37.7) |
3 | 19 (13.8) |
>3 | 20 (14.5) |
Further lines of systemic therapy – n (%) | 41 (29.7) |
Radiotherapy during immunotherapy –n (%) | 38 (27.5) |